[April 20, 2018]

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy 2018 - Competitive Landscape and Pipeline & Market Analysis - ResearchAndMarkets.com

The "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about the marketed and pipeline drugs across this Immunotherapy.

The report provides the detailed analysis of 190+ products along with 60+ companies involved. Celgene Corporation and bluebird bio has been granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA (News - Alert) for bb2121 Anti-BCMA CAR-T Cell Therapy for Relapsed and Refractory Multiple Myeloma.

Products covered by Phase

• Phase II, Phase I and IND
• Pre-clinical and Discovery

Scope

• The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
• The report provides pipeline produts under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

• Aikang Biomedical Technology
• Arbele
• Aurora BioPharma
• Autolus
• Avacta Life Sciences
• Beijing Biohealthcare Biotechnology
• Beijing Immunochina Medical Science & Technology
• bluebird bio
• CARMA Therapeutics
• Carsgen Therapeutics
• Eureka Therapeutics
• Gilead Sciences
• GlaxoSmithKline
• Guangdong Zhaotai InVivo Biomedicine
• Hebei Senlang Biotechnology
• Helix BioPharma
• iCell Gene Therapeutics
• Innovative Cellular Therapeutics
• Juno Therapeutics
• MabVax Therapeutics
• Marino Biotechnology
• Maxcyte
• Noile-Immune Biotech
• Novartis
• OncoTAb
• Oncternal Therapeutics
• Persongen Biomedicine (Suzhou)
• Poseida Therapeutics
• Shanghai Unicar-Therapy Bio-medicine Technology
• Shire
• Sinobioway Cell Therapy
• Sorrento Therapeutics
• Symvivo
• Takara Bio
• Ziopharm Oncology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7m2p6t/chimeric_antigen?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180420005670/en/

[ Back To TMCnet.com's Homepage ]